These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28879786)

  • 1. Pharmacological management of type 2 diabetes: what's new in 2017?
    Scheen AJ
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1383-1394. PubMed ID: 28879786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
    Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
    Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
    Elbelt U
    Dtsch Med Wochenschr; 2018 Jun; 143(11):772-776. PubMed ID: 29807374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Chudleigh RA; Bain S
    Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
    Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of anti-diabetes drugs.
    Younk LM; Lamos EM; Davis SN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1239-57. PubMed ID: 27268470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcome trials of glucose-lowering therapies.
    Khunti K; Davies MJ; Seidu S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):237-249. PubMed ID: 32403956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.